Difference between revisions of "Part:BBa K2200007"
Awesome Zz (Talk | contribs) |
|||
(6 intermediate revisions by the same user not shown) | |||
Line 3: | Line 3: | ||
<partinfo>BBa_K2200007 short</partinfo> | <partinfo>BBa_K2200007 short</partinfo> | ||
− | GAL4 is a transcription factor of galactose metabolism related genes, which recognizes and binds the promoter UAS through its N-terminal DNA binding domain, and assembles and transcribes the RNA polymerase II complex through its C-terminal activation domain.According to previous studies, it's activity can be up-regulated by adding the P65 sequence. | + | GAL4 is a transcription factor of galactose metabolism related genes, which recognizes and binds the promoter UAS through its N-terminal DNA binding domain, and assembles and transcribes the RNA polymerase II complex through its C-terminal activation domain. According to previous studies, it's activity can be up-regulated by adding the P65 sequence. |
− | |||
===Usage and Biology=== | ===Usage and Biology=== | ||
− | + | iGEM_SFLS team improved part BBa_K1470002 (https://parts.igem.org/Part:BBa_K1470002) to create a more efficient transcriptional amplification strategy system (TAS) by fusing part of the NF-KB p65 protein to the DNA-binding domain of GAL4 protein. The TAS was designed to improve the function of tumor-specific promotors mutant hTERT. They are able to inhibit gene expression to particular cells, but they are always weak promoters which can not sufficiently initiate the transcription of downstream genes. As a result, the TAS system is used to enhance the activity of such promoters with cell type specificity. | |
− | + | ||
<span class='h3bb'>Sequence and Features</span> | <span class='h3bb'>Sequence and Features</span> | ||
<partinfo>BBa_K2200007 SequenceAndFeatures</partinfo> | <partinfo>BBa_K2200007 SequenceAndFeatures</partinfo> | ||
− | + | Uncomment this to enable Functional Parameter display | |
===Functional Parameters=== | ===Functional Parameters=== | ||
+ | <p>The function of this part was demonstrated by an experiment in a previous paper [1]. CMV promotor was selectively inserted in GAL4-P65, GAL4 and GAL4-VP64 (VP64, a transcription factor) gene. GAL4-p65 was also inserted downstream the tumor-specific promotor hTERT. The function of these promotors and transcription factors were measured by the expression of fluoresce in bladder cancer cell lines T24, 5637, and human foreskin fibroblasts.</p> | ||
+ | <p>The results in the paper ([1]-fig.2) showed that the luciferase activities were obviously up-regulated by the CMV-GAL4-P65 vector group, which means it can enhance the expression of downstream gene.</p> | ||
+ | |||
+ | ===Reference=== | ||
+ | [1] Huang X, Zhuang C, Zhuang C, et al. An enhanced hTERT promoter-driven CRISPR/Cas9 system selectively inhibits the progression of bladder cancer cells. Molecular Biosystems, 2017, 13(9): 1713-1721. | ||
+ | |||
<partinfo>BBa_K2200007 parameters</partinfo> | <partinfo>BBa_K2200007 parameters</partinfo> | ||
− |
Latest revision as of 23:24, 1 November 2017
Gal4 transcription factor is a positive regulator.
GAL4 is a transcription factor of galactose metabolism related genes, which recognizes and binds the promoter UAS through its N-terminal DNA binding domain, and assembles and transcribes the RNA polymerase II complex through its C-terminal activation domain. According to previous studies, it's activity can be up-regulated by adding the P65 sequence.
Usage and Biology
iGEM_SFLS team improved part BBa_K1470002 (https://parts.igem.org/Part:BBa_K1470002) to create a more efficient transcriptional amplification strategy system (TAS) by fusing part of the NF-KB p65 protein to the DNA-binding domain of GAL4 protein. The TAS was designed to improve the function of tumor-specific promotors mutant hTERT. They are able to inhibit gene expression to particular cells, but they are always weak promoters which can not sufficiently initiate the transcription of downstream genes. As a result, the TAS system is used to enhance the activity of such promoters with cell type specificity. Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 710
Illegal XhoI site found at 218 - 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 886
- 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI site found at 137
Uncomment this to enable Functional Parameter display
Functional Parameters
The function of this part was demonstrated by an experiment in a previous paper [1]. CMV promotor was selectively inserted in GAL4-P65, GAL4 and GAL4-VP64 (VP64, a transcription factor) gene. GAL4-p65 was also inserted downstream the tumor-specific promotor hTERT. The function of these promotors and transcription factors were measured by the expression of fluoresce in bladder cancer cell lines T24, 5637, and human foreskin fibroblasts.
The results in the paper ([1]-fig.2) showed that the luciferase activities were obviously up-regulated by the CMV-GAL4-P65 vector group, which means it can enhance the expression of downstream gene.
Reference
[1] Huang X, Zhuang C, Zhuang C, et al. An enhanced hTERT promoter-driven CRISPR/Cas9 system selectively inhibits the progression of bladder cancer cells. Molecular Biosystems, 2017, 13(9): 1713-1721.